For map in e-/A^3 units to make sense one needs to obtain F000, which may be more tricky than one may think. Interesting, how Coot does this given just a set of Fourier map coefficients?
Pavel On Wed, Nov 28, 2012 at 12:21 PM, Greg Costakes <gcost...@purdue.edu> wrote: > You stated that the map is set to 3 sigma, but what is the e-/A^3? In > Coot I often find that my fo-fc map needs to be maxed out (max sigma) in > order to get to an acceptable e-/A^3. It is possible that your fo-fc map at > 3 sigma has an e-/A^3 of 0.04 or something low like that. > > > ------------------------------------------------------------------------------- > Greg Costakes > PhD Candidate > Department of Structural Biology > Purdue University > Hockmeyer Hall, Room 320 > 240 S. Martin Jischke Drive, West Lafayette, IN 47907 > > > -------------------------------------------------------------------------------- > > > ------------------------------ > *From: *"Jon Read" <jon.r...@astrazeneca.com> > *To: *CCP4BB@JISCMAIL.AC.UK > *Sent: *Wednesday, November 28, 2012 10:48:04 AM > *Subject: *[ccp4bb] Strange density > > > Anyone see anything like this before? The data is 1.7Angstrom data with > good statistics. The picture shows the solid FoFc density contoured at 3 > Sigma in light brown and -3 Sigma in purple. The density is odd as it > appears to be bound to a peptide carbonyl with no other obvious > interactions with the protein. There is a characteristic tail at one end. > > > > > > > > ------------------------------ > > AstraZeneca UK Limited is a company incorporated in England and Wales with > registered number: 03674842 and a registered office at 2 Kingdom Street, > London, W2 6BD. > > *Confidentiality Notice: *This message is private and may contain > confidential, proprietary and legally privileged information. If you have > received this message in error, please notify us and remove it from your > system and note that you must not copy, distribute or take any action in > reliance on it. Any unauthorised use or disclosure of the contents of this > message is not permitted and may be unlawful. > > *Disclaimer:* Email messages may be subject to delays, interception, > non-delivery and unauthorised alterations. Therefore, information expressed > in this message is not given or endorsed by AstraZeneca UK Limited unless > otherwise notified by an authorised representative independent of this > message. No contractual relationship is created by this message by any > person unless specifically indicated by agreement in writing other than > email. > > *Monitoring: *AstraZeneca UK Limited may monitor email traffic data and > content for the purposes of the prevention and detection of crime, ensuring > the security of our computer systems and checking compliance with our Code > of Conduct and policies. > >
